Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis

Oct 19 2018

• By Brenda Sandburg

Courthouse Inscription

Related Content

Amneal Loses Bid For 180-Day Generic Exclusivity On Namenda XR

Jan 30 2018

Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy

Jul 25 2018

Restasis Patent Review Back On Track As Federal Circuit Quashes Mohawk Tribe's Sovereign Immunity Claim

Jul 23 2018

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

Oct 17 2017

Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays

Sep 03 2014

Related Companies

Teva Pharmaceutical Industries Ltd.

Allergan plc

Indivior plc

Amneal Pharmaceuticals, Inc.

Additional Topics

United States Generic Drugs Legal Issues Regulation FDA BioPharmaceutical

More from Generics

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window